Endotype-driven precision medicine in chronic rhinosinusitis.

Hongfei Lou1, Chengshuo Wang1, Luo Zhang1,2,3

  • 1Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.

Summary

Precision medicine advances chronic rhinosinusitis (CRS) care by identifying endotypes. Type 2 inflammation biomarkers predict treatment response in CRS with nasal polyps (CRSwNP), guiding personalized therapies.